Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › RVPH

Reviva Pharmaceuticals

RVPH Rare disease Lead: Phase 3 ★ Read the deep dive → 8 Biotech Distilled articles ↓ 18 filings & releases ↓ Cash $19.9M (Jun 30, 2026) ↓ 8 verdicts ↓
CardiovascularDermatologyNeurologyRespiratory Small Molecule

Market cap $4.8M 13.1M shares (10-Q, Aug 13, 2026) × $0.368 close Nov 6, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. cash runway corporate updateJul 2027cash runway corporate update, Jul 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Capital (as filed)

Cash
$19.9M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$2.1M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$19.9M cash, runway July 2027 per the update of Aug 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Reviva Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2025-12-15 Watch Scientific Due Diligence for Brilaroxazine: Reviva Pharmaceuticals (RVPH) Science is compelling and Phase 3 data is solid, but the stock is a binary bet on the FDA pre-NDA meeting outcome with a broken balance sheet, making it a watch-list name rather than an outright buy.
  2. 2025-12-23 Hold Update: Reviva Pharmaceuticals (RVPH) – The Bear Case is Here – FDA Requires Second Phase 3 Trial The single-trial regulatory gamble failed; the FDA requires a second Phase 3 trial, creating a 2.5-year delay and massive financing need, but the science remains valid and a partnership/buyout could still recover value for holders.
  3. 2026-01-25 Avoid Update: Reviva Pharmaceuticals (RVPH) - The Cleanup Begins Nasdaq deadline forces an imminent reverse split followed by dilutive equity offering; the next 60 days are about financial engineering, not drug development, making the stock uninvestable until the dust settles.
  4. 2026-03-07 Avoid UPDATE: Reviva Pharmaceuticals (RVPH) - The Inevitable Arrives The 1-for-20 reverse split is Step 1 of the dilution playbook; Step 2 (a large equity offering to fund RECOVER-2) is imminent, and the stock should be avoided until financing is fully priced in.
  5. 2026-03-21 Avoid UPDATE: Reviva Pharmaceuticals (RVPH) - Reviva's $10M Dilution Spiral The $10M survival offering landed with a 55% single-day crash, massive warrant overhang, and proceeds far short of the $50-60M needed for RECOVER-2, leaving the corporate vehicle in a severe financial distress cycle.
  6. 2026-03-29 Avoid UPDATE: Reviva Pharmaceuticals (RVPH) - The Post-Offering Cap Table New passive hedge fund buyer and severe dilution of legacy holders confirm the corporate vehicle is still broken; RECOVER-2 remains underfunded and the warrant overhang caps any near-term upside.
  7. 2026-05-14 Avoid UPDATE: Reviva Pharmaceuticals (RVPH) - The Nasdaq Exit Nasdaq delisting to OTCQB confirms the financial death spiral, restricts institutional buyers, and makes the next financing more dilutive; the science is intact but the corporate vehicle is fundamentally broken.
  8. 2026-08-13 Avoid UPDATE: Reviva Pharmaceuticals (RVPH) - The Trade-Off Gets Explicit RECOVER-2 enrollment slips a full year to 1H 2027 as Reviva trades speed for a 2046 patent runway via a new-form filing; the $50M+ funding gap, warrant overhang, and going-concern language are all unchanged, with Q4 2026 FDA feedback on the new form as the next binary catalyst.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (18)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)